Core Viewpoint - Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (Baicheng Pharmaceutical) is actively engaging with various investment institutions to discuss its subsidiary, Saimo Pharmaceutical's recent developments, collaborations with the University of Science and Technology of China Hangzhou Institute, and advancements in core technology platforms and innovative drug research [1] Group 1: Saimo Pharmaceutical Developments - Saimo Pharmaceutical has made significant progress in production capacity and has successfully bid in the 11th national centralized drug procurement, with 12 products expected to be awarded, showcasing its competitive market position [2] - The company has established a production facility covering over 260 acres, with 163,000 square meters of GMP-compliant buildings and laboratories, and has completed 617 project verifications and registered 461 projects [2] Group 2: Collaboration with University of Science and Technology of China - Baicheng Pharmaceutical has been collaborating with the University of Science and Technology of China Hangzhou Institute since 2022, focusing on innovative drug development in areas such as biomedicine and respiratory diseases [3] - The partnership includes establishing a research platform, enhancing technical discussions, and sharing resources between academia and industry [3] Group 3: Core Technology Platforms - The company has three main technology platforms: the innovative drug research center, the high-end complex formulation platform, and the traditional Chinese medicine and natural drug research center, promoting multi-field collaborative development [4] - The innovative drug research center is led by experienced professionals and has over 15 new drug pipelines targeting neurology, autoimmune diseases, and oncology [4] Group 4: Innovative Drug Pipeline Progress - Baicheng Pharmaceutical has more than 15 self-developed new drug pipelines, including projects for treating obstructive sleep apnea and autoimmune inflammation, with three class 1 new drugs having received IND approvals [5] - The company plans to accelerate overseas collaborations in innovative drug development and enhance its AI drug platform and organoid platform to improve research efficiency [5]

Group 1: Company Overview - The company is Hangzhou Baicheng Pharmaceutical Technology Co., Ltd., with stock code 301096 and abbreviation Baicheng Pharmaceutical [1] Group 2: Subsidiary Progress - Subsidiary Simmer Pharmaceutical has a construction area of approximately 260 acres, with 163,000 square meters of GMP-standard facilities [2] - Simmer has completed 617 project verifications and registered 461 projects, ranking among the top in the country [2] - In the 11th batch of national drug centralized procurement, Simmer is expected to win bids for 12 products, enhancing its production capacity and market share [2] Group 3: Collaborations - The company collaborates closely with the Hangzhou Institute of Advanced Studies at the University of Science and Technology of China, establishing a joint R&D center since 2022 [3] - The joint laboratory has been recognized as a key laboratory in Zhejiang Province for 2024, focusing on innovative drug development in various fields [3] Group 4: Core Technology Platforms - The company has three main technology platforms: innovative drug R&D center, high-end complex formulation platform, and traditional Chinese medicine and natural drug R&D center [3] - Over 15 new drug pipelines have been established, covering areas such as neurobiology, autoimmune diseases, and oncology [3] Group 5: Innovative Drug Development - The company is advancing over 15 self-developed new drug pipelines, including drugs for OSA-related daytime sleepiness, autoimmune inflammation, and tumors [3] - The drug Bios-0618 for OSA is currently in the clinical phase II enrollment stage, while Bios-0625 for autoimmune inflammation is in the IND application stage [3] - The company has obtained 3 IND approvals for its first-class new drug and is actively pursuing overseas collaborations to enhance growth potential [3]